GenAI has rocketed from moonshot to reality. In this industry of winner takes most, no company wants to be left behind!

To flesh out the reality for FIs in Capital Markets, Celent surveyed buy side, FMI, and sell side executives in roles tied to innovation. Questions included their sentiment towards GenAI, the state of adoption by area, the relevance of use case areas by value chain as well as the success factors they have identified through their experience piloting and implementing GenAI use cases in capital markets.

Survey participants tended to be innovation frontrunners and hence are ahead on the GenAI adoption curve compared to the majority of institutions. Nevertheless, the findings are startling, with a slow start to in production use cases due to accelerate.